Jefferies has recently initiated Syndax Pharmaceuticals Inc (SNDX) stock to Buy rating, as announced on June 28, 2024, according to Finviz. Earlier, on January 31, 2024, Scotiabank had reduced the ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

On September 30, 2024, State Street Corp made a significant addition to its investment portfolio by acquiring 148,491 shares of Syndax Pharmaceuticals Inc (NASDAQ:SNDX) at a price of $19.25 per share.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Syndax Pharmaceuticals , Inc. (NASDAQ:SNDX) is at a pivotal juncture in its journey as a biopharmaceutical company focused on developing innovative therapies for cancer and... ByInvesting.com ...

Jefferies has recently initiated Syndax Pharmaceuticals Inc (SNDX) stock to Buy rating, as announced on June 28, 2024, according to Finviz. Earlier, on January 31, 2024, Scotiabank had reduced the ...

Barclays analyst Peter Lawson assigned a Buy rating to Syndax Pharmaceuticals (SNDX – Research Report) today and set a price target of $33.00. The company’s shares closed yesterday at $18.20.

The stock of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) has decreased by -0.66 when compared to last closing price of 18.32. Despite this, the company has experienced a -2.62% fall in its stock price ...

On Wednesday, Syndax Pharmaceuticals (NASDAQ:SNDX) shares retained Buy rating and $36.00 price target from B.Riley, in light of the anticipated significant developments for the company. The focus is ...